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ABSTRACT
Objectives To conduct a feasibility randomised 
controlled trial of risperidone for the treatment of 
aggression in adults with traumatic brain injury (TBI).
Design Multicentre, parallel design, placebo 
controlled (1:1 ratio) double- blind feasibility trial 
with an embedded process evaluation. No statistical 
comparison was performed between the two study 
groups.
Setting Four neuropsychiatric and neurology 
outpatient clinics in London and Kent, UK.
Participants Our aim was to recruit 50 patients 
with TBI over 18 months. Follow- up participants 
at 12 weeks using a battery of assessment scales 
to measure changes in aggressive behaviour and 
irritability (Modified Overt Aggression Scale (MOAS)- 
primary outcome, Irritability Questionnaire) as well as 
global functioning (Glasgow Outcome Scale- Extended, 
Clinical Global impression) and quality of life (EQ- 
5D- 5L, SF-12), mental health (Hospital Anxiety and 
Depression Scale) and medication adverse effects 
(Udvalg for Kliniske Undersøgelser).
Results Six participants were randomised to the 
active arm of the trial and eight to the placebo arm 
over a 10- month period (28% of our target). Two 
participants withdrew because of adverse events. 
Twelve out of 14 (85.7%) patients completed a follow- 
up assessment at 12 weeks. At follow- up, the scores 
of all outcome measures improved in both groups. 
Placebo group showed numerically better score change 
according to the primary outcome MOAS. No severe 
adverse events were reported. The overall rate of 
adverse events remained low. Data from the process 
evaluation suggest that existence of specialised 
TBI follow- up clinics, availability of a dedicated 
database of TBI patients’ clinical details, simple 
study procedures and regular support to participants 
would enhance recruitment and retention in the trial. 
Feedback from participants showed that once in the 
study, they did not find the trial procedure onerous.
Conclusions It was not feasible to conduct a 
successful randomised trial of risperidone versus 
placebo for post- TBI aggression using the methods we 
deployed in this study. It is not possible to draw any 
definitive conclusion about risperidone’s efficacy from 
such a small trial.
Trial registration number ISRCTN30191436
INTRODUCTION
A high proportion of patients with traumatic 
brain injury (TBI) show aggression after the 
injury (see table 1). Aggression causes distress 
to patients and their families, can hinder 
rehabilitation, lead to social isolation, loss of 
family/friends’ support, unnecessary use of 
restraint and medication, and hospitalisation. 
In addition, it has financial implications for 
patients, their families and society as a whole.
The rates of post- TBI aggression vary widely 
(see table 1) depending on the population 
studied, definition used for aggression, time 
after injury, severity of injury and presence of 
comorbidities. There is no universally accepted 
definition of aggression, therefore, researchers 
have used different arbitrary cut- off scores 
using different rating scales to define aggres-
sion which produced a wide range of incidence 
rates. Also, the boundary between aggression, 
agitation, irritability, anger and disinhibi-
tion is not clear as different studies included 
different symptoms for assessment. The popu-
lation point prevalence of post- TBI aggression 
is unclear. Most studies included patients from 
clinics or rehabilitation centres, therefore, it is 
Strengths and limitations of this study
 ► We used a stringent randomised controlled trial 
methodology for a feasibility trial.
 ► Once recruited in the study, the participants felt 
supported.
 ► A process evaluation helped to identify factors that 
may support or impede successful recruitment in 
future trials of interventions for post- traumatic brain 
injury aggression.
 ► Recruitment has remained a major problem.
 ► Regulatory authority delays hampered patient 
recruitment.
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difficult to know the true extent of the problem within the 
TBI population in general as most of them suffer from a 
mild TBI (70%–85%)1 and do not attend any clinic or reha-
bilitation centre. The rate also varies depending on patient 
or informant rating as informants tend to report a higher 
rate of aggression than the patients themselves.2
Post- TBI aggression is mostly reactive in nature and not 
premeditated. Verbal aggression and aggression to objects 
are more common than physical aggression to others.3
It is proposed that in the period immediately following 
TBI, aggression is caused by organic factors such as 
post- TBI confusion, frontal lobe damage, left cerebral 
lesion.4 However, in the chronic stage, psychosocial factors 
play a more important role in causing aggression.5 6 Many 
preinjury and postinjury factors affect the rate and the 
severity of aggression. For example, premorbid factors 
such as antisocial personality trait including aggressive 
tendency, history of psychiatric disorders, impulsivity, 
alcohol and substance abuse, low educational and socio-
economic status are shown to predispose aggression 
after TBI.5 6 Similarly, post- TBI factors such as loss of 
job, alcohol and substance abuse, comorbid anxiety and 
depression are shown to be associated with a higher rate 
of post- TBI aggression.5 6
Neural substrate of aggression
It is postulated that either a reduction in the top- 
down control from the prefrontal cortex or an over-
active limbic system (particularly affecting anterior 
cingulate gyrus and amygdala) may lead to aggression. 
These regions are responsible for cognitive interpreta-
tion of emotional stimuli which determines a person’s 
response to potentially threatening stimuli. It has been 
suggested that reduced serotonin and increased dopa-
mine and nor- adrenaline activity in cortical areas, and 
reduced GABA and acetylcholine activity in limbic areas 
modulate aggression in humans.7 Therefore, we can 
expect that a reduction in cortical dopamine by antipsy-
chotics, nor- adrenaline by beta- blockers and increase 
in serotonin by selective serotonin reuptake inhibitors, 
and stabilisation of GABA/glutamate imbalance in the 
limbic region by antiepileptics should lead to reduced 
aggression. However, randomised controlled trial 
(RCT) based evidence does not support these simple 
assumptions (see table 2). It could be because the role 
of any particular neuromodulator in aggression is far 
from clear and they may cause aggression through indi-
rect mechanisms. For example, serotonin is involved in 
influencing impulsivity and dopamine is responsible for 
reward punishment behaviour rather than aggression 
per se, and nor- adrenaline acts as a stress hormone and 
influences the ‘fight- or- flight’ response.8
Evidence on pharmacological intervention for post-TBI 
aggression
Since Deb and Crownshaw’s9 original systematic review on 
the effectiNeuropsychiatry Inventory- Aggressionveness 
of psychotropics on neurobehavioural symptoms of TBI, 
several reviews have been published on this.10–19 Find-
ings from all the RCTs on pharmacotherapy for post- TBI 
aggression are summarised in table 2. A number of studies 
have shown methylphenidate’s (MPH) effectiveness in 
improving post- TBI cognitive impairment and some-
times apathy symptoms.14 However, only two very small 
trials (see table 2) have specifically looked at its effect on 
post- TBI anger and aggression, one showed superiority of 
MPH and the other did not.
There are four RCTs involving amantadine, three of 
which are from the same author (see table 2). Two of 
the studies used Neuropsychiatric Inventory- Irritability 
(NPI- I) Scale, which measures irritability rather than 
aggression.20 NPI is not an ideal instrument to assess 
post- TBI aggression as it was originally designed for 
dementia patients. Also, half of the eight items in NPI- A 
(NPI- Aggression) subscale do not directly relate to aggres-
sion. Most studies showed large placebo effect. Overall 
finding from these studies is equivocal. One other very 
small (n=10) cross- over study of amantadine that was 
reported by a different group did not show any significant 
intergroup difference in outcome. There is now a major 
concern about dopaminergic drugs’ serious adverse 
effects such as impulse control disorder like pathological 
gambling, hypersexuality and binge eating.21
There are four very small cross- over trials on beta- 
blockers, three of which were reported by the same group 
(see table 2). Three RCTs used cross- over design and 
one parallel design. Two studies showed superiority of 
beta- blockers, one was non- significant and one showed 
partial superiority. These studies have not always used 
standardised outcome measures and sample sizes are very 
small. Additionally, both the treatment period and the 
follow- up are of short duration. Therefore, it is difficult 
to draw any definite conclusion about beta- blockers’ effi-
cacy in treating post- TBI aggression. Furthermore, most 
studies used a very high dose of beta- blockers which has 
the potential to cause severe adverse effects such as bron-
chospasm and hypotension.
Evidence on psychopharmacological intervention of 
aggression in non-TBI population
As there is no strong evidence to support any specific phar-
macological intervention to treat post- TBI aggression, 
we extrapolated data from RCTs among other patient 
groups. Old generation antipsychotics by blocking non- 
specific dopaminergic activity (particularly involving the 
nigrostriatal pathway) and also for their anticholinergic 
effect cause troublesome adverse effects such as extrapy-
ramidal and cardiac symptoms and also show a higher 
tendency to develop serious adverse effects such as neuro-
leptic malignant syndrome. On the other hand, new 
generation antipsychotics provide better tolerability and 
a broader therapeutic effect by specific action on the D2 
dopaminergic system (particularly involving the mesocor-
tical pathway) as well as serotonergic and nor- adrenergic 
systems. However, they are prone to produce metabolic 
4 Deb S, et al. BMJ Open 2020;10:e036300. doi:10.1136/bmjopen-2019-036300
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syndrome. Therefore, as expected most evidence is based 
on new generation antipsychotics especially risperidone.
There are six placebo controlled RCTs involving chil-
dren with autism spectrum disorder and/or intellectual 
disabilities (ID), all showed superiority of risperidone 
over placebo (number needed to treat is 3).22 There are 
three small RCTs among adults with ID, two showed supe-
riority of risperidone (0.5–4 mg/day) and one showed 
no significant intergroup difference among risperidone, 
haloperidol and placebo.23 There are two large RCTs both 
showing superiority of risperidone over placebo in treating 
aggression in patients with schizophrenia.24 There are 
seven RCTs of risperidone (0.5–2 mg/ day) showing its 
superiority over placebo in treating behaviour and psychi-
atric symptoms of dementia (BPSD), five of them showed 
specific effect on aggression.25 However, because of a 
high rate of cerebrovascular mortality and extrapyramidal 
adverse effects associated with antipsychotics these drugs 
Table 2 RCTs of pharmacological interventions of aggression in post- TBI adults
Author (year) Drug dose RCT design No of participants Outcome measure Findings
Psychostimulant
Mooney (1993)55 Methylphenidate 30 
mg daily
Parallel 
single blind 
design
Traetment:19
Placebo:19
POMS- Anger hostility 
score
Significantly 
effective in anger 
reduction
Speech (1993)56 Methylphenidate 
0.3 mg/kg two times 
a day
Cross- over 12 closed head 
injury patients
KAS- belligerence 
score
NS
Dopaminergic
Schnieder (1999)57 Amantadine 100–300 
mg/day
Cross- over 10 patients with TBI Neurobehavioural 
Rating Scale
NS
Hammond (2014)58 Amantadine 100 mg 
two times a day
Parallel 
design
76 NPI- I+NPI- A NS for the whole 
group but in 
a subgroup, 
amantadine was 
significantly better
Hammond (2015)59 Amantadine 100 mg 
two times a day
Parallel 
design
168 NPI- I NS, both groups 
showed large 
improvements
Hammond (2017)60 Amantadine 100 mg 
two times a day
Parallel 
design
118 NPI- I Two items out of 
many showed 
significantly better 
outcome in the 
amantadine group
Beta- blockers
Greendyke (1986a)61 Propranolol 80–520 
mg/day
Cross- over 9 patients with ABI Observed frequency 
of aggressive 
behaviour
Propranolol 
significantly 
reduced assaultive 
behaviour
Greendyke (1986b)62 Pindolol 10–60 mg/ 
day
Cross- over 11 patients with ABI 
(possible overlap 
with participants in 
1986a study; not 
known)
Observed frequency 
of aggressive 
behaviour
Pindolol significantly 
reduced assaultive 
behaviour
Greendyke (1989)63 Pindolol 5–20 mg/day Cross- over 10 patients with 
ABI
OAS NS
Brooke (1992)64 Propranolol 
60–420 mg/day 
(recommended 
maximum is 320 mg/
day)
Parallel 
design
Propranolol:11
Placebo:10
OAS Propranolol group 
showed less intense 
but same frequency 
of assaults 
compared to the 
placebo group 
received more 
physical restraints
ABI, acquired brain injury; KAS, Katz Adjustment Scale; NPI- A, Neuropsychiatry Inventory- Aggression; NPI- I, NPI- Irritability; NS, non- 
significant; OAS, Overt Aggression Scale; POMS, Profile of Mood States; RCT, randomised controlled trial; TBI, traumatic brain injury.
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are not recommended for use for BPSD. Some prelimi-
nary evidence also exists in favour of olanzapine, aripip-
razole and clozapine in treating aggression in different 
patient groups which we have not discussed here because 
of lack of space.26 At present no strong evidence exists in 
support of other psychotropics such as mood stabilisers, 
antidepressants, benzodiazepines.26 27
Justification for our study design
As there is no strong evidence to support any specific 
drug for the treatment of aggression in TBI, but evidence 
shows that risperidone may reduce aggression among 
people with other neuropsychiatric conditions, we set 
out to examine the feasibility of conducting a placebo 
controlled trial of risperidone among adults who show 
aggression following TBI.
AIM
1. To assess feasibility of a future definitive placebo con-
trolled RCT of risperidone for post- TBI aggression in 
adults.
2. Perform a sample size calculation needed for a future 
definitive RCT.
3. Through process evaluation identify factors that may 
support or impede successful recruitment in future 
trials.
METHODS
We conducted a multicentre parallel design placebo 
controlled (1:1 ratio) double- blind feasibility RCT of 
risperidone with an embedded process evaluation.
We have summarised the design in this paper. For a 
full description please see our trial protocol paper.28 
Aggression was defined as any form of behaviour directed 
towards the goal of harming or injuring another living 
being who is motivated to avoid such treatment,’29 and 
included verbal aggression, and physical aggression to 
others, property and self, excluding agitation. Rather 
than using an arbitrary cut- off score on a rating scale, we 
asked clinicians to refer any patient to the trial that they 
were considering prescribing medication for the treat-
ment of post- TBI aggression.
PATIENT AND PUBLIC INVOLVEMENT
The study was developed jointly with a group of 18 adults 
with TBI from a Headway centre in London, UK. They 
were not participants of the study. A patient with TBI was 
part of the project group. An advisory group of patients 
with TBI who did not take part in the study met every 
few months to discuss the project and provide feed-
back through a facilitator (clinical psychologist). They 
attended a day centre which was not associated to any of 
the recruiting centres.
RECRUITMENT
Our aim was to recruit from four centres in London, UK. 
These included adults with TBI who attended outpatient 
clinics, three saw patients with various neuropsychi-
atric disorders including patients with TBI and one was 
a neurology clinic dedicated to adult patients with TBI 
only. The researcher completed a baseline prerandomis-
ation outcome assessment on those patients who agreed 
to take part. A local clinician completed the Clinical 
Global Impression- Severity (CGI- S) scale30 and Udvalg 
for Kliniske Undersøgelser (UKU) adverse effect scale31 
and arranged for appropriate physical examination. Rele-
vant blood test results were supposed to be collected from 
participant’s case notes if available.
SAMPLE SIZE
As this was a feasibility study, we did not carry out a formal 
power calculation but estimated that 40–50 is a reason-
able number for a feasibility study which would allow us 
to carry out a sample size calculation for the full future 
proposed RCT.32 A general guide for number of partici-
pants necessary for a feasibility study is 30–50 patients.33
Inclusion/exclusion criteria
Inclusion criteria
1. Aged between 18 and 65 years.
2. Patients with a confirmed clinical diagnosis of TBI us-
ing the Mayo Clinic criteria,34 which happened at least 
6 months prior to recruitment.
3. Referred to the clinicians for the management of ag-
gression and for whom the clinician is considering a 
pharmacological intervention for aggression after in-
vestigating and addressing physical, psychological and 
social triggers.
Exclusion criteria
1. Patient suffering from post- traumatic amnesia.
2. Comorbid serious mental illness such as schizophrenia 
and other psychoses, bipolar disorder, major depres-
sive disorder, personality disorder and dementia.
3. Patients who were already on an antipsychotic drug or 
any other drug that may interact with risperidone at 
the time of randomisation.
4. Any other contraindication for using risperidone in-
cluding a previous history of severe adverse events.
5. Patients with no fixed abode or any other reason for 
which compliance with study medication and monitor-
ing could pose a major problem.
6. A history of definite neurogenic seizures within the last 
3 months.
ACTIVE DRUG DOSE
We used a flexible dose of risperidone. We started with 
1 mg once daily dose and increased the dose if necessary, 
to up to 4 mg/day. Equivalent number of placebo capsules 
were also administered to the appropriate participants. 
The placebo capsules looked exactly the same as the 
risperidone capsules. The researcher followed up partic-
ipants by telephone every week to assess improvement or 
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emergence of any adverse events using informally a scale 
similar to CGI.30 The researcher liaised with the local 
clinician every week to provide feedback on the partici-
pant’s progress. The local clinicians decided whether a 
dose increase or decrease is warranted based on the infor-
mation provided by the researcher and where necessary 
by personally reviewing the participant in their clinic. 
Local clinicians were allowed to use PRN (as required) 
medication if necessary. The researcher provided partici-
pants with a proforma to keep a log of medication intake. 
The researcher checked this during the weekly telephone 
follow- up. At the end of the trial the researcher counted 
the number of any leftover medicine to assess adherence.
OUTCOME MEASURES
Feasibility outcome measures
Our criteria for demonstrating success of the feasi-
bility study were: (1) recruitment of at least 80% of the 
sample who met inclusion criteria after screening, and 
(2) completion of follow- up assessments at 12 weeks by at 
least 75% of the randomised participants.
Clinical outcome measures
Primary outcome measure
We used Modified Overt Aggression Scale (MOAS) to 
assess improvement in aggression. The MOAS is a simple 
and widely used 4- item scale that measures verbal aggres-
sion along with physical aggression towards other people, 
property and self. The MOAS35 is a valid and reliable 
instrument which is validated in the TBI population36 
and has been used widely in the assessment of post- TBI 
aggression and its treatment (see tables 1 and 2). Lower 
MOAS values indicate lower levels of aggression.
Secondary outcome measures
1. Glasgow Outcome Scale- Extended version (GOS- E),37 
which is a widely used global outcome measure of post- 
TBI functioning,
2. Irritability Questionnaire (IRQ),38 (patient and carer 
version), this is a well- validated scale and is used in this 
trial as irritability is often associated with aggression.
3. Hospital Anxiety and Depression Scale (HADS),39 
which is a well standardised easy to use scale for the as-
sessment of depressive and anxiety symptoms. We used 
HADS as both anxiety and depressive symptoms are 
common after TBI and we have previously established 
its cut- off score for brain injury patients.40
4. CGI- Improvement (CGI- I) and CGI- S Scales30 which 
are well validated and are used widely as secondary 
outcome measures in clinical trials,
5. UKU Scale31 to assess adverse effects of risperidone.
6. Two widely used quality of life (QoL) measures, name-
ly EQ- 5D- 5L41 and SF-1242 to assess participant’s QoL 
as the ultimate goal of the intervention is not only 
symptoms reduction but to improve participant’s QoL. 
These two measures would be useful in calculating 
quality- adjusted life years in any future definitive RCT.
All these measures were used at baseline and at 12 weeks 
follow- up.
We used a proforma specifically designed for this study 
to collect demographic data such as age, gender and also 
other relevant information such as cause and severity of 
TBI.
Researcher completed MOAS based on information 
from both the patients and the carers (where available).
Concealment and randomisation
Remote web- based randomisation was undertaken 
through a fully automated service operated by an 
external organisation ‘Sealed Envelope’. Our aim was to 
randomise an equal number of participants to risperidone 
and placebo. We used random permuted blocks strat-
ified by study centres (n=4). Sealed Envelope designed 
the randomisation list and labelled all medicine bottles 
including placebo with randomisation codes before 
sending to study centres. There was a 24- hour telephone 
number available for the clinicians and research team if 
the randomisation code needed to be broken. Everyone 
involved in the study including the participants, their 
carers, local clinicians, researchers, general practitioners 
were blind to this allocation.
Statistical analyses of clinical data
The primary outcome was the patient- reported MOAS 
score, measured at 12 weeks follow- up. As this is a feasi-
bility study, no formal hypothesis tests were performed to 
statistically compare the two study groups, but descriptive 
data are presented.
Table 3 Patient demographics
Variable Category Placebo Risperidone
No patients – 8 6
Gender Female 3 (38%) 1 (17%)
Male 5 (62%) 5 (83%)
Age – 43.1±11.3 
years
39.3±8.7 years
TBI cause Assault 2 (25%) 0 (0%)
Fall 3 (38%) 1 (17%)
Road Traffic 
Accident
3 (38%) 3 (50%)
Other 0 (0%) 2 (33%)
Initial severity* Mild 2 (33%) 1 (17%)
Moderate 1 (17%) 3 (50%)
Severe 3 (50%) 2 (33%)
History of 
coma
No 5 (62%) 3 (50%)
Yes 3 (38%) 3 (50%)
History of PTA No 5 (62%) 2 (33%)
Yes 3 (38%) 4 (67%)
Summary statistics are: mean±SD or number (percentage).
*Missing data for two patients in Placebo group.
PTA, post- traumatic amnesia; TBI, traumatic brain injury.
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All secondary outcomes were analysed descriptively, 
with no formal hypothesis tests performed. The frequency 
of adverse events as per the UKU Scale was calculated at 
follow- up.
Process evaluation
A process evaluation using a qualitative method examined 
trial recruitment, and the feasibility and acceptability of 
trial procedures from the perspective of patients and 
their carers. We undertook semistructured qualitative 
interviews with trial participants, and their carers, purpo-
sively sampled to represent site and treatment allocation.
Interviews were conducted using a bespoke topic guide. 
As the qualitative interviews generated a rich dataset it is 
beyond the scope of this paper to present all the details 
here. The topic guide was developed under the following 
broad headings; (1) Background information (how TBI 
has affected participants’ lives in general), (2) Interven-
tions (was it difficult to comply with the intervention?), (3) 
Outcome (how did they feel about the overall outcome 
measures at the end of the study?), (4) Trial procedures 
(taking part in questionnaire completion, support from 
the research team etc), (5) Factors influencing participa-
tion and retention (eg, factors hampering vs helping with 
participation). These interviews were audio- recorded, 
transcribed and analysed using a thematic framework 
approach43 and managed using NVivo44 computer 
software.
RESULTS
The demographic characteristics of study participants are 
summarised in table 3. The mean age of patients was 43 
and 39 in the placebo and risperidone groups respectively. 
Over 60% of both groups were male. Fourteen of the 43 
(32.6%) eligible patients were recruited between March 
2017 and January 2018 (see figure 1). Eight patients 
received placebo and six risperidone (see figure 1). 
However, two participants from the placebo group and 
one from the risperidone group withdrew. Two withdrew 
due to adverse events and for one participant follow- up 
data were available. Therefore, MOAS data were calcu-
lated for five risperidone and seven placebo group partic-
ipants (see table 4), giving an 85.7% follow- up rate. Verbal 
aggression was the most common type of aggression 
exhibited by the participants along with aggression to 
property, but a minority also showed aggression directed 
Figure 1 Flow chart of study recruitment.
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towards self and others. Three participants received 2 mg 
and two received 4 mg risperidone at the end point. No 
postintervention blood test results were available from 
participants’ case notes. No one had a psychiatric diag-
nosis such as schizophrenia, major depressive disorders, 
anxiety disorders, personality disorder or dementia. No 
one received concomitant psychotropic medication or 
PRN (as required) medication.
Feasibility outcome data
Our original recruitment target was 50 participants 
from four centres over 18 months (0.69 patient/centre/
month). One centre did not recruit any patient and 
another centre recruited only one patient who did not 
complete the trial. The overall recruitment rate was 0.3 
patient/centre/month across all four centres (21% of the 
target rate) over 10 months period. The recruitment rate 
from a research active University centre was 0.78/month 
(113% of the target rate). This centre was dedicated to 
adults with TBI and held a patient database which helped 
the researcher to screen for potential recruits. Because 
of regulatory authority delays the total recruitment time 
available was shortened by 8 months.
Quantitative outcome data
The data suggest slightly higher MOAS values at base-
line in the placebo group. At 12 weeks, MOAS values had 
reduced in both groups, to a similar level (see tables 4 and 
5). Therefore, the placebo group showed a larger change 
in total MOAS values and its subscores. In order to aid a 
possible future sample size calculation (using an analysis 
of covariance approach), the association between MOAS 
total score at baseline and 12 weeks was assessed. Spear-
man’s rank correlation gave a correlation of 0.04 between 
Table 4 Primary outcome MOAS patient ratings
Time point Group N Mean±SD Median (IQR) Range
Baseline* Placebo 7 11.6±9.6 8 (2 to 24) 2 to 25
Risperidone 5 5.0±3.0 6 (2 to 8) 2 to 9
Week 12 Placebo 7 2.0±2.4 1 (0 to 3) 0 to 7
Risperidone 5 2.2±3.9 0 (0 to 6) 0 to 9
Change† Placebo 7 −9.5±10.5 −4 (−23 to 1) −25 to 1
Risperidone 5 −2.8±4.8 −2 (−8 to 2) −9 to 3
*Summary statistics only for patients with values at 12 weeks.
†Calculated as value at week 12 minus value at baseline.
MOAS, Modified Overt Aggression Scale.
Table 5 MOAS subdomain scores
Outcome Time point
Placebo Risperidone
N Summary N Summary
MOAS patient rating Baseline* 7 4.7±2.4 5 3.4±1.7
  Verbal Week 12 7 1.4±1.3 5 1.0±1.4
  Change† 7 −3.3±2.7 5 −2.4±2.3
MOAS patient rating Baseline* 7 2.0±2.1 5 0.2±0.4
  Against property Week 12 7 0.3±0.8 5 0.2±0.4
  Change† 7 −1.7±2.4 5 0.0±0.0
MOAS patient rating Baseline* 7 0.6±0.8 5 0.4±0.9
  Autoaggression Week 12 7 0.0±0.0 5 0.0±0.0
  Change† 7 −0.6±0.8 5 −0.4±0.9
MOAS patient rating Baseline* 7 0.3±0.8 5 0.0±0.0
  Against people Week 12 7 0.0±0.0 5 0.2±0.4
  Change† 7 −0.3±0.8 5 0.2±0.4
MOAS carer rating Baseline* 5 8.4±8.4 3 10.3±6.5
  Total score Week 12 5 2.8±3.1 3 3.7±3.8
  Change† 5 −5.6±5.6 3 −6.7±3.2
*Summary statistics only for patients with values at 12 weeks.
†Calculated as value at week 12 minus value at baseline.
MOAS, Modified Overt Aggression Scale.
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timepoints. This suggests little relationship between the 
scores at the two time points.
The secondary outcome measures showed mixed 
results (see table 6). Numerically the score changes in the 
IRQ and HADS- Anxiety were slightly greater in the risper-
idone group whereas HADS- Depression score change was 
slightly greater in the placebo group. A similar picture was 
revealed for the QoL scales scores (SF-12 and EQ- 5D- 5L), 
and also GOS- E (see table 6). According to CGI- I, 40% 
in the risperidone group and 33% in the placebo group, 
respectively, were ‘much’ or ‘very much improved’ at 
follow- up. Patient MOAS score correlated with both base-
line (r: 0.78; p<0.001) and follow- up patient IRQ severity 
score (r: 0.64; p=0.03).
No severe adverse events were reported. The overall 
rate of adverse events remained low although it was 
slightly higher numerically in the risperidone group.
An approximate sample size calculation done by the 
study statistician (PB) shows that for a 5% significance 
level and 90% power, 72 patients per group and 144 in 
total will be required. Allowing for a 20% attrition rate, a 
total of 180 patients would need to be recruited.
Qualitative outcome data
Eight patients and two of their carers were interviewed 
and the data were analysed by the researcher (LA), under 
the supervision from the qualitative investigator (TW).
Key factors exerting a positive influence on partici-
pation reported by patients and their carers included a 
belief in the positive benefit of research. This may have 
been expressed as (1) a perception that the trial may 
help to achieve their ‘desire to get better’, or (2) satisfy 
an altruistic motivation to participate in research that 
might help other people in a similar situation. Some also 
reported (3) previous positive experiences in taking part 
in research. Also, significant to maintaining engagement 
were (4) the straightforward research procedures and 
(5) the high level of trust and support engendered by 
weekly telephone contact from the researcher (LA) and 
(6) good relations with the referring doctor. Participation 
was also associated with (7) a higher educational level of 
the participants.
The analysis showed that the key reasons for patients not 
taking part in the study were: (1) a reluctance to change 
treatment, (2) perceived adverse effects of the study 
medication, (3) lack of understanding of the reason why 
the study is undertaken as this was not clearly explained 
to them, (4) lack of insight into their own condition, so 
the potential participants did not see their behaviour as 
a problem needing any intervention, (5) unwillingness to 
engage with treatment regime or trial procedures and (6) 
objection to randomisation manifested as a reluctance 
particularly on the part of the carers regarding poten-
tial allocation into the placebo arm which they thought 
might make the patient’s behaviour worse and difficult 
to manage.
Furthermore, many participants, particularly those who 
had memory and attention problem, found it tiring to 
complete so many assessment measures some of which 
were quite long. Similarly, memory problems may have 
affected the consent process thus making some potential 
patients ineligible for recruitment.
DISCUSSION
Given the very small sample size, it is not possible to draw 
any definite conclusion from the interpretation of the 
outcome data.
Clinical findings
In the current study, risperidone did not show superiority 
over placebo at follow- up as measured using total MOAS 
score (the primary outcome). No clear pattern emerged 
in secondary outcomes. Like previous studies most of the 
aggression in our study was primarily verbal in nature.3 
Also, as expected, there was a correlation between patient 
reported MOAS and IRQ scores suggesting a clinical 
Table 6 Secondary outcome measures (IRQ, GOS- E, EQ- 
5D- 5L, SF-12, HADS)
Outcome Time point
Placebo Risperidone
N mean±SD N mean±SD
IRQ patient Baseline* 7 34±6 5 37±19
  Severity Week 12 7 26±7 5 25±14
  Change† 7–8±9 5–13±13
IRQ carer Baseline* 5 10±4 5 14±5
  Severity Week 12 5 7±4 5 7±4
  Change† 3–3±2 5–6±2
GOS- E Baseline* 7 6.4±1.1 5 6.6±1.5
Week 12 7 6.4±1.1 5 6.8±1.6
Change† 7 0.0±0.0 5 0.2±0.5
EQ VAS Baseline* 7 53±24 5 61±10
Week 12 7 57±30 5 64±21
Change† 7 4±11 5 3±18
SF-12 Baseline* 7 44±13 5 51±10
  Physical Week 12 7 43±11 5 47±12
  Change† 7 0±14 5–3±5
SF-12 Baseline* 7 34±14 5 30±12
  Mental Week 12 7 41±15 5 40±19
  Change† 7 7±18 5 9±13
HADS anxiety Baseline* 7 8.6±3.8 5 9.6±6.9
Week 12 7 6.7±3.8 5 6.8±7.2
Change† 7–1.9±3.5 5–2.8±1.8
HADS depression Baseline* 7 9.9±5.5 5 4.8±4.2
Week 12 7 7.9±4.7 5 5.0±3.9
Change† 7–2.0±2.8 5 0.2±2.9
*Summary statistics only for patients with values at 12 weeks.
†Calculated as value at week 12 minus value at baseline.
GOS- E, Glasgow Outcome Scale- Extended; HADS, Hospital 
Anxiety and Depression Scale; IRQ, Irritability Questionnaire.
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association between irritability and aggression. Carer 
reported mean MOAS values are numerically higher 
than the patient reported values both at baseline and at 
follow- up. This is in keeping with previous studies3 but 
difficult to comment on given the small sample size and 
skewed distribution of MOAS values. This could be due 
to patient’s poor insight to their problems, using denial 
as a psychological defence and impaired self- awareness.3
Risperidone dosage
There was no evidence of non- adherence to medication 
in this trial. It is difficult to determine the right thera-
peutic window for the risperidone dosage as a lower 
dose may be ineffective and a higher dose may produce 
unwanted adverse effects. This is even more difficult to 
decide for patients with TBI as there is no research- based 
evidence to calibrate the dose specifically for this patient 
group. Therefore, we had to look into dosage used in 
RCTs for non- TBI patient groups for a reference point. 
We used a lower dose of risperidone than that used for 
the treatment of schizophrenia for the following reasons: 
(1) a high dose of risperidone is likely to lower seizure 
threshold and the patients with TBI are vulnerable to 
develop seizures, we, therefore, started low and went slow, 
(2) reports from one laboratory have shown detrimental 
effect on experimentally induced TBI rodents’ behaviour 
and cognition from chronic use of high dose risperidone, 
although this finding has not been replicated in humans45 
(3) RCTs of risperidone among adults with ID23 and also 
dementia25 used a lower dose (2–4 mg/day), (4) in the 
UK clinicians use low- dose risperidone to treat post- TBI 
aggression (0.5–4 mg/day) and (5) we were advised by 
the patient advisory group to use low dose as they were 
worried about risperidone’s adverse effects at a high dose. 
Also, it appears that a low dose (2 mg/day) was sufficient 
for most participants in our study.
Feasibility outcome
The purpose of the study was to assess feasibility of a future 
definitive RCT. We concluded that it may not be feasible 
to conduct a definitive trial using the approach we took 
in this feasibility study. Our rate of recruitment fell short 
of our original goal because two of the four centres failed 
to recruit participants. However, if the rate of recruitment 
achieved in the two active sites, were replicated across 
other centres, a definitive RCT would be feasible.
We also concluded that an adequate number of partic-
ipants could not be recruited in a future definitive full 
RCT from neuropsychiatry clinics alone. We believe 
that to recruit an adequate number of participants in 
the future, it would be necessary to broaden the range 
of services to include neurorehabilitation centres and 
possibly trauma centres.
Our experience shows that research active centres are 
likely to recruit an adequate number of participants in a 
future RCT as they already have the infrastructure and 
the patients attending these centres are already familiar 
with research procedures and may have already taken part 
in other research studies. However, the downside may be 
that patients may have already been recruited in one or 
more studies, therefore, would be difficult to recruit into 
yet another study.
We found the way the project is presented to the poten-
tial participant is of utmost importance. Therefore, we 
feel that a face- to- face meeting with the potential patients 
explaining the study properly than a telephone call is 
more likely to increase the chance of recruitment. Regular 
support such as weekly telephone calls (as was the case in 
our study) is likely to retain the patient in the study.
We found that it is important to carefully choose exclu-
sion criteria as in our study initial criterion of excluding 
patients with a history of epilepsy meant exclusion of 
some otherwise eligible patients. We later revised the 
exclusion criterion to ‘history of a definite neurogenic 
seizure within the last 3 months.’
Recommendations from the feasibility study
A successful definitive RCT would require: (1) recruitment 
through specialised TBI clinics, (2) clinics having databases 
of potentially eligible patients, (3) a senior clinician engaged 
enough to facilitate the study and (4) clinical colleagues 
who are enthusiastic and prepared to help with the study, 
(5) regulatory approvals in place well before the planned 
start of recruitment (6) availability of sufficient resources to 
be able to spend time with potential recruits in a face to face 
meeting to describe the study, (7) regular support through 
either regular visits or telephone checks, (8) simple study 
procedures to optimise retention in the study, for example, 
make the study medication easily accessible and keep the 
number of questionnaires and tests to absolute minimum 
(9) information in an accessible format as many patients 
with TBI would have difficulty in concentrating and memo-
rising complex information and (10) some form of non- 
pharmacological intervention such as ‘anger management’ 
alongside study medication to increase the recruitment and 
retention rate.
Strengths and limitations
The RCT design in our study is robust and would create 
minimum selection, performance, detection, attrition, 
reporting, concealment and other biases. Once recruited 
in the study, the participants felt supported. A process eval-
uation helped to get positive and negative feedbacks from 
the participants. However, recruitment remained a major 
problem and delays in obtaining regulatory approvals 
hampered patient recruitment. The total number of partic-
ipants was too small. Although we achieved our feasibility 
target of 75% retention, we failed to recruit at least 80% of 
the sample who met inclusion criteria after screening.
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